News

Darzalex Faspro combo benefits patients new to MM and transplant

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to significantly better outcomes for people who are newly diagnosed with multiple myeloma and transplant eligible. That’s according to four-year data from the Phase 3…

FDA delays its decision on earlier Abecma treatment for RRMM

The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to be used earlier in the treatment of difficult-to-manage multiple myeloma. Abecma currently is FDA-approved for adults with relapsed or refractory multiple myeloma (RRMM) who…

Foundation awards $21M in grants for multicenter myeloma research

Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly diagnosed high-risk multiple myeloma and smoldering multiple myeloma. Smoldering multiple myeloma is an early, slow-growing blood cancer that can develop into active multiple…

Survival rates by race found similar with Abecma in myeloma study

Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but overall survival rates were similar between hard-to-treat Black, Hispanic, and white patients, a new U.S. study found. “We see that Black and white patients with multiple…

Elrexfio for RRMM recommended in EU for conditional approval

A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be conditionally approved for treating people in Europe with relapsed or refractory multiple myeloma (RRMM). The recommendation, from the EMA’s Committee for Medicinal Products…